Partial compliance with antipsychotics and its impact on patient outcomes

References

• Rupp A, Keith SJ. The costs of schizophrenia: assessing the burden. Psychiatr Clin North Am 1993; 16(2)413–23
   PubMed Web of Science ®Google Scholar
• Wasylenki DA. The cost of schizophrenia. Can J Psychiatry 1994; 39(9 Suppl2)S65–69
   Web of Science ®Google Scholar
• Lader M. Pharmacological prevention of relapse. Kaohsiung J Med Sci 1998; 14(7)448–57
   PubMedGoogle Scholar
• Weiden PJ, Zygmunt A. Medication noncompliance in schizophrenia: Part I. Assessment. J Pract Psych Behav Health 1997; 3: 106–10
   Google Scholar
• Lacro JP, Dunn LB, Dolder CR, et al. of relapse in schizophrenia. Schizophr Bull 1995; 21(3)419–29
   PubMed Web of Science ®Google Scholar
• Olfson M, Mechanic D, Hansell S, Boyer C, Walkup J, Weiden P. Predicting medication noncompliance after hospital discharge among patients with schizophrenia. Psychiatr Serv 2000; 51: 216–22
   PubMed Web of Science ®Google Scholar
• Kozma, C, Grogg, A. Medication compliance and hospitalization in schizophrenia. Presented at College of Psychiatric and Neurologic Pharmacists 6th Annual Meeting; May, 1–4, 2003; Charleston, , SC.
   Google Scholar
• Oehl M, Hummer M, Fleischhacker W. Compliance with antipsychotic treatment. Acta Psychiatr Scand 2000; 102(Suppl 407)83–6
   Google Scholar
• Cramer J, Rosenheck R. Compliance with medication regimens for mental and physical disorders. Psychiatr Serv 1998; 49: 196–201
   PubMed Web of Science ®Google Scholar
• Docherty, JP, Grogg, AL, Kozma, C, , et al. Antipsychotic maintenance in schizophrenia: Partial compliance and clinical outcome. Presented at the 41st annual meeting of the American College of Neuropsychopharmacology; December, 8–12, 2002; San Juan, , Puerto Rico.
   Google Scholar
• Keith S, Kane J. Partial compliance and patient consequences in schizophrenia: Our patients can do better. J Clin Psychiatry 2003; 64: 1308–15
   PubMed Web of Science ®Google Scholar
• Robinson D, Woerner M, Alvir J, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 1999; 56: 241–7
   PubMed Web of Science ®Google Scholar
• Valenstein M, Copeland LA, Owen R, Blow FC, Visnic S. Adherence assessments and the use of depot antipsychotics in patients with schizophrenia. J Clin Psychiatry 2001; 62(7)545–51
   PubMed Web of Science ®Google Scholar
• Weiden PJ, Kozma C, Grogg A, Locklear J. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv 2004; 55(8)886–91
   PubMed Web of Science ®Google Scholar
• Fenton WS, Blyler CR, Heinssen RK. Determinants of medication compliance in schizophrenia: Empirical and clinical findings. Schizophr Bull 1997; 23(4)637–51
   PubMed Web of Science ®Google Scholar
• Byerly M, Fisher R, Whatley K, et al. A comparison of electronic monitoring vs. clinician rating of antipsychotic adherence in outpatients with schizophrenia. Psychiatry Res 2005; 133: 129–33
   PubMed Web of Science ®Google Scholar
• Diaz E, Levine H, Sullivan M, et al. Use of the Medication Event Monitoring System to estimate medication compliance in patients with schizophrenia. J Psychiatry Neurosci 2001; 26: 325–9
   PubMed Web of Science ®Google Scholar
• Farmer K. Methods for measuring and monitoring medication regimen adherence in clinical trials and in clinical practice. Clin Ther 1999; 21: 1074–90
   PubMed Web of Science ®Google Scholar
• Eaddy M, Grogg A, Locklear J. Assessment of compliance with antipsychotic treatment and resource utilization in a Medicaid population. Clin Ther 2005; 27: 263–72
   PubMed Web of Science ®Google Scholar
• Valenstein M, Copeland L, Blow F, et al. Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission. Med Care 2002; 40: 630–9
   PubMed Web of Science ®Google Scholar
• Ayuso-Gutierrez JL, del Rio Vega JM. Factors influencing relapse in the long-term course of schizophrenia. Schizophr Res 1997; 28(2–3)199–206
   PubMed Web of Science ®Google Scholar
• Gilmer TP, Dolder CR, Lacro JP, et al. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am J Psychiatry 2004; 161(4)692–9
   PubMed Web of Science ®Google Scholar
• Herings R, Erkens J. Increased suicide attempt rate among patients interrupting use of atypical antipsychotics. Pharmacoepidemiol Drug Saf 2003; 12: 423–4
   PubMed Web of Science ®Google Scholar
• Dolder C, Lacro J, Dunn L, Jeste D. Antipsychotic medication adherence: is there a difference between typical and atypical agents?. Am J Psychiatry 2002; 159: 103–8
   PubMed Web of Science ®Google Scholar
• Byerly M, Fisher R, Carmody T, Rush A. A trial of compliance therapy in outpatients with schizophrenia or schizoaffective disorder. J Clin Psychiatry 2005; 66: 997–1001
   PubMed Web of Science ®Google Scholar
• Velligan DI, Mueller J, Wang M, et al. Use of environmental supports among patients with schizophrenia. Psychiatr Serv 2006; 57(2)219–24
   PubMed Web of Science ®Google Scholar
• Novak-Grubic V, Tavcar R. Predictors of noncompliance in males with first-episode schizophrenia, schizophreniform and schizoaffective disorder. Eur Psychiatry 2002; 17: 148–54
   PubMed Web of Science ®Google Scholar
• Freudenreich O, Cather C, Evins A, Henderson C, Goff D. Attitudes of schizophrenia outpatients toward psychiatric medications: relationship to clinical variables and insight. J Clin Psychiatry 2004; 65: 1372–6
   PubMed Web of Science ®Google Scholar
• Krausz M, Moritz S, Naber D, Lambert M, Andresen B. Neuroleptic-induced extrapyramidal symptoms are accompanied by cognitive dysfunction in schizophrenia. Eur Psychiatry 1999; 14: 84–8
   PubMed Web of Science ®Google Scholar
• Amador XF, Strauss DH, Yale SA, Gorman JM. Awareness of illness in schizophrenia. Schizophr Bull 1991; 17(1)113–32
   PubMed Web of Science ®Google Scholar
• Hogan TP, Awad AG, Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med. 1983; 13(1)177–83
   PubMed Web of Science ®Google Scholar
• Adams SG, Jr, Howe JT. Predicting medication compliance in a psychotic population. J Nerv Ment Dis 1993; 181(9)558–60
   PubMed Web of Science ®Google Scholar
• Kane J, Eerdekens M, Lindenmayer J-P, Keith S, Lesem M, Karcher K. Long-acting injectable risperidone: Efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry 2003; 160: 1125–32
   PubMed Web of Science ®Google Scholar
• Robinson D, Woerner M, Alvir J, Bilder R, Hinrichsen G, Lieberman J. Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder. Schizophr Res 2002; 57: 209–19
   PubMed Web of Science ®Google Scholar
• Svedberg B, Mesterton A, Cullberg J. First-episode non-affective psychosis in a total urban population: A 5-year follow-up. Soc Psychiatry Psychiatr Epidemiol 2001; 36(7)332–7
   PubMed Web of Science ®Google Scholar
• Kampman O, Laippala P, Vaananen J, et al. Indicators of medication compliance in first-episode psychosis. Psychiatry Res 2002; 110(1)39–48
   PubMed Web of Science ®Google Scholar
• Verdoux H, Lengronne J, Liraud F, et al. Medication adherence in psychosis: Predictors and impact on outcome. A 2-year follow-up of first-admitted subjects. Acta Psychiatr Scand 2000; 102(3)203–10
   PubMed Web of Science ®Google Scholar
• Perkins DO. Adherence to antipsychotic medications. J Clin Psychiatry 1999; 60(Suppl 21)25–9
   PubMed Web of Science ®Google Scholar
• Fleischhacker W, Eerdekens M, Karcher K, et al. Treatment of schizophrenia with long acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. J Clin Psychiatry 2003; 64: 1250–1257
   PubMed Web of Science ®Google Scholar
• Schou M. The combat of non-compliance during prophylactic lithium treatment. Acta Psychiatr Scand. 1997; 95(5)361–3
   PubMed Web of Science ®Google Scholar
• Miner CR, Rosenthal RN, Hellerstein DJ, Muenz LR. Prediction of compliance with outpatient referral in patients with schizophrenia and psychoactive substance use disorders. Arch Gen Psychiatry 1997; 54(8)706–12
   PubMed Web of Science ®Google Scholar
• Tattan T, Creed F. Negative symptoms of schizophrenia and compliance with medication. Schizophr Bull 2001; 27: 149–55
   PubMed Web of Science ®Google Scholar
• Donohue G, Owens N, O'Donnell C, Burke T, Moore L, Tobin A, O'Callaghan E. Predictors of compliance with neuroleptic medication among inpatients with schizophrenia: a discriminant function analysis. Eur Psychiatry 2001; 16(5)293–8
   PubMed Web of Science ®Google Scholar
• Prouteau A, Verdoux H, Briand C, et al. Cognitive predictors of psychosocial functioning outcome in schizophrenia: a follow-up study of subjects participating in a rehabilitation program. Schizophr Res 2005; 77: 343–53
   PubMed Web of Science ®Google Scholar
• Kemp R, David A. Psychological predictors of insight and compliance in psychotic patients. Br J Psychiatry. 1996; 169(4)444–50
   PubMed Web of Science ®Google Scholar
• Cuffel B, Alford J, Fischer E, Owen R. Awareness of illness in schizophrenia and outpatient treatment adherence. J Nerv Ment Dis 1996; 184: 653–9
   PubMed Web of Science ®Google Scholar
• Brebion G, Bressan R, Amador X, Malaspina D, Gorman J. Medications and verbal memory impairment in schizophrenia: the role of anticholinergic drugs. Psychol Med 2004; 34: 369–74
   PubMed Web of Science ®Google Scholar
• Kamali M, Kelly L, Gervin M, Browne S, Larkin C, O'Callaghan E. Psychopharmacology: insight and comorbid substance misuse and medication compliance among patients with schizophrenia. Psychiatr Serv 2001; 52(2)161–3–166
   Web of Science ®Google Scholar
• Margolese H, Malchy L, Negrete J, Tempier R, Gill K. Drug and alcohol use among patients with schizophrenia and related psychoses: levels and consequences. Schizophr Res 2004; 67: 157–66
   PubMed Web of Science ®Google Scholar
• Owen R, Fischer E, Booth B, Cuffel B. Medication noncompliance and substance abuse among patients with schizophrenia. Psychiatr Serv 1996; 47: 853–8
   PubMed Web of Science ®Google Scholar
• Hellewell JS. Patients’ subjective experiences of antipsychotics: clinical relevance. CNS Drugs 2002; 16(7)457–71
   PubMed Web of Science ®Google Scholar
• Baptista T, Zarate J, Joober R, et al. Drug induced weight gain, an impediment to successful pharmacotherapy: focus on antipsychotics. Curr Drug Targets 2004; 5: 279–99
   PubMed Web of Science ®Google Scholar
• Guthrie S. Clinical issues associated with maintenance treatment of patients with schizophrenia. Am J Health Syst Pharm 2002; 59(Suppl 5)S19–24
   Google Scholar
• Wallace M. Real progress – the patient's perspective. Int Clin Psychopharmacol 2001; 16(Suppl 1)S21–4
   Google Scholar
• Casey DE. Barriers to progress – the impact of tolerability problems. Int Clin Psychopharmacol 2001; 16(Suppl 1)S15–19
   Google Scholar
• Gerlach J. Improving outcome in schizophrenia: the potential importance of EPS and neuroleptic dysphoria. Ann Clin Psychiatry 2002; 14(1)47–57
   PubMedGoogle Scholar
• Fleischhacker WW, Meise U, Gunther V, Kurz M. Compliance with antipsychotic drug treatment: influence of side effects. Acta Psychiatr Scand Suppl 1994; 382: 11–15
   PubMedGoogle Scholar
• Hummer M, Kemmler G, Kurz M, Kurzthaler I, Oberbauer H, Fleischhacker WW. Sexual disturbances during clozapine and haloperidol treatment for schizophrenia. Am J Psychiatry 1999; 156(4)631–3
   PubMed Web of Science ®Google Scholar
• Lieberman J, Stroup T, McEvoy J, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New Engl J Med 2005; 353: 1209–23
   PubMed Web of Science ®Google Scholar
• Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999; 156(11)1686–96
   PubMed Web of Science ®Google Scholar
• Ganguli R. Weight gain associated with antipsychotic drugs. J Clin Psychiatry 1999; 60(Suppl 21)20–4
   PubMedGoogle Scholar
• Kasper S, Muller-Spahn F. Review of quetiapine and its clinical applications in schizophrenia. Expert Opin Pharmacother 2000; 1(4)783–801
   PubMedGoogle Scholar
• Masand PS. Weight gain associated with psychotropic drugs. Expert Opin Pharmacother 2000; 1(3)377–89
   PubMedGoogle Scholar
• Nasrallah H. A review of the effect of atypical antipsychotics on weight. Psychoneuroendocrinology 2003; 28: 83–96
   PubMed Web of Science ®Google Scholar
• Keck PE, Jr, McElroy SL. Aripiprazole: a partial dopamine D2 receptor agonist antipsychotic. Expert Opin Investig Drugs 2003; 12(4)655–66
   PubMed Web of Science ®Google Scholar
• Masand PS, Schwartz TL, Wang X, et al. Prescribing conventional antipsychotics in the era of novel antipsychotics: informed consent issues. Am J Ther 2002; 9: 484–7
   PubMedGoogle Scholar
• Marder SR, McQuade RD, Stock E, et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res 2003; 61(2–3)123–36
   PubMed Web of Science ®Google Scholar
• Nasrallah H. A review of the effect of atypical antipsychotics on weight. Psychoneuroendocrinology 2003; 28: 83–96
   PubMed Web of Science ®Google Scholar
• Masand PS, Gupta S. Long-term adverse effects of atypical antipsychotics. Psychiatr Pract 2000; 6: 299–309
   PubMedGoogle Scholar
• Meaney AM, Smith S, Howes OD, et al. Effects of long-term prolactin-raising antipsychotic medication on bone mineral density in patients with schizophrenia. Br J Psychiatry 2004; 184: 503–50
   PubMed Web of Science ®Google Scholar
• Goodnick PJ, Rodriguez L, Santana O. Antipsychotics: impact on prolactin levels. Expert Opin Pharmacother 2002; 3(10)1381–91
   PubMedGoogle Scholar
• Arvanitis LA, Miller BG. Multiple fixed doses of “Seroquel” (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Biol Psychiatry 1997; 42(4)233–46
   PubMed Web of Science ®Google Scholar
• Kinon BJ, Gilmore JA, Liu H, et al. Hyperprolactinemia in response to antipsychotic drugs: characterization across comparative clinical trials. Psychoneuroendocrinology 2003; 28(Suppl 2)69–82
   PubMed Web of Science ®Google Scholar
• Bilder R, Goldman R, Volavka J, et al. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry 2002; 159: 1018–28
   PubMed Web of Science ®Google Scholar
• Marder SR. Facilitating compliance with antipsychotic medication. J Clin Psychiatry 1998; 59(Suppl 3)21–5
   PubMedGoogle Scholar
• Wallace M. Real progress–the patient's perspective. Int Clin Psychopharmacol 2001; 16(Suppl 1)S21–4
   Google Scholar
• Fleischhacker W, Oehl M, Hummer M. Factors influencing compliance in schizophrenia patients. J Clin Psychiatry 2003; 64(Suppl 16)10–13
   PubMed Web of Science ®Google Scholar
• Loffler W, Kilian R, Toumi M, Angermeyer M. Schizophrenic patients’ subjective reasons for compliance and noncompliance with neuroleptic treatment. Pharmacopsychiatry 2003; 36: 105–12
   PubMed Web of Science ®Google Scholar
• Kemp R, Kirov G, Everitt B, Hayward P, David A. Randomised controlled trial of compliance therapy. 18-month follow up. Br J Psychiatry 1998; 172: 413–19
   PubMed Web of Science ®Google Scholar
• Aguglia E, De Vanna M, Onor M, Ferrara D. Insight in persons with schizophrenia: effects of switching from conventional neuroleptics to atypical antipsychotics. Prog Neuropsychopharmacol Biol Psychiatry 2002; 26: 1229–33
   PubMed Web of Science ®Google Scholar
• Harvey P, Green M, McGurk S, Metlzer H. Changes in cognitive functioning with risperidone and olanzapine treatment: a large-scale, double-blind, randomized study. Psychopharmacology 2003; 169: 404–11
   PubMed Web of Science ®Google Scholar
• Rittmannsberger H, Pachinger T, Keppelmuller P, Wancata J. Medication adherence among psychotic patients before admission to inpatient treatment. Psychiatr Serv 2004; 55: 174–9
   PubMed Web of Science ®Google Scholar
• Masand PS, Schwartz TL, Wang X, et al. Prescribing conventional antipsychotics in the era of novel antipsychotics: informed consent issues. Am J Ther 2002; 9: 484–7
   PubMedGoogle Scholar
• Carpenter WT, Jr. Maintenance therapy of persons with schizophrenia. J Clin Psychiatry 1996; 57(Suppl 9)10–18
   PubMedGoogle Scholar
• Schooler NR, Keith SJ, Severe JB, et al. Relapse and rehospitalization during maintenance treatment of schizophrenia. The effects of dose reduction and family treatment. Arch Gen Psychiatry 1997; 54(5)453–63
   PubMed Web of Science ®Google Scholar
• Gerlach J. Depot neuroleptics in relapse prevention: advantages and disadvantages. Int Clin Psychopharmacol 1995; 9(Suppl 5)17–20
   PubMed Web of Science ®Google Scholar
• Walburn J, Gray R, Gournay K, Quraishi S, David A. Systematic review of patient and nurse attitudes to depot antipsychotic medication. Br J Psychiatry 2001; 179: 300–7
   PubMed Web of Science ®Google Scholar
• Kane J. Strategies for improving compliance in treatment of schizophrenia by using a long-acting formulation of an antipsychotic: clinical studies. J Clin Psychiatry 2003; 64(Suppl 16)34–40
   PubMed Web of Science ®Google Scholar
• Davis, JM, Matalon, L, Watanabe, MD, Blake, L, Metalon, L. [corrected to Matalon L). Depot antipsychotic drugs. Place in therapy. Drugs 1994;47(5):741–73, (Review) [Erratum in: Drugs 1994;48(4):616].
   PubMed Web of Science ®Google Scholar
• Rifkin A, Quitkin F, Klein DF. Fluphenazine decanoate, oral fluphenazine, and placebo in treatment of remitted schizophrenics. II. Rating scale data. Arch Gen Psychiatry 1977; 34(10)1215–9
   PubMed Web of Science ®Google Scholar
• Schooler NR, Levine J, Severe JB. Depot fluphenazine in the prevention of relapse in schizophrenia: evaluation of a treatment regimen [proceedings]. Psychopharmacol Bull 1979; 15(2)44–7
   PubMedGoogle Scholar
• Gerlach J. Oral versus depot administration of neuroleptics in relapse prevention. Acta Psychiatr Scand Suppl 1994; 382: 28–32
   PubMedGoogle Scholar
• Kane J. Strategies for improving compliance in treatment of schizophrenia by using a long-acting formulation of an antipsychotic: clinical studies. J Clin Psychiatry 2003; 64(Suppl 16)34–40
   PubMed Web of Science ®Google Scholar
• Fleischhacker W, Eerdekens M, Karcher K, et al. Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. J Clin Psychiatry 2003; 64: 1250–7
   PubMed Web of Science ®Google Scholar
• Lasser R, Bossie C, Gharabawi G, Turner M. Patients with schizophrenia previously stabilized on conventional depot antipsychotics experience significant clinical improvements following treatment with long-acting risperidone. Eur Psychiatry 2004; 19: 219–25
   PubMed Web of Science ®Google Scholar
• Llorca, PM, Devos, E, Eerdekens, M, , et al. Re-hospitalisation rates with long-acting risperidone injection are lower than those reported for other antipsychotics. Presented at the XXIII CINP Congress, Montreal, Canada, June 23–27, 2002.
   Google Scholar
• Martin S, Libretto S, Pratt D, Brewin J, Huq Z, Saleh B. Clinical experience with the long-acting injectable formulation of the atypical antipsychotic, risperidone. Curr Med Res Opin 2003; 19: 298–305
   PubMed Web of Science ®Google Scholar
• Gharabawi G, Bossie C, Zhu Y, Mao L, Lasser R. An assessment of emergent tardive dyskinesia and existing dyskinesia in patients receiving long-acting, injectable risperidone: Results from a long-term study. Schizophr Res 2005; 77: 129–39
   PubMed Web of Science ®Google Scholar
• Hornung WP, Klingberg S, Feldmann R, et al. Collaboration with drug treatment by schizophrenic patients with and without psychoeducational training: results of a 1-year follow-up. Acta Psychiatr Scand 1998; 97(3)213–21
   PubMed Web of Science ®Google Scholar
• Pekkala E, Merinder L. Psychoeducation for schizophrenia (Cochrane Review). Cochrane Library ;Issue 2002; 4: 1–6
   Google Scholar
• Zygmunt A, Olfson M, Boyer CA, et al. Interventions to improve medication adherence in schizophrenia. Am J Psychiatry 2002; 159(10)1653–66
   PubMed Web of Science ®Google Scholar
• Smith TE, Hull JW, Goodman M, et al. The relative influences of symptoms, insight, and neurocognition on social adjustment in schizophrenia and schizoaffective disorder. J Nerv Ment Dis 1999; 187(2)102–8
   PubMed Web of Science ®Google Scholar